Prostate cancer, version 1.2016 Journal Article


Authors: Mohler, J. L.; Armstrong, A. J.; Bahnson, R. R.; D'Amico, A. V.; Davis, B. J.; Eastham, J. A.; Enke, C. A.; Farrington, T. A.; Higano, C. S.; Horwitz, E. M.; Hurwitz, M.; Kane, C. J.; Kawachi, M. H.; Kuettel, M.; Lee, R. J.; Meeks, J. J.; Penson, D. F.; Plimack, E. R.; Pow-Sang, J. M.; Raben, D.; Richey, S.; Roach, M.; Rosenfeld, S.; Schaeffer, E.; Skolarus, T. A.; Small, E. J.; Sonpavde, G.; Srinivas, S.; Strope, S. A.; Tward, J.; Shead, D. A.; Freedman-Cass, D. A.
Article Title: Prostate cancer, version 1.2016
Abstract: The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naive disease.
Keywords: risk; active surveillance; radical prostatectomy; prognostic value; mitoxantrone plus prednisone; beam radiation-therapy; classification-system; pretreatment nomogram; cycle progression score; genomic classifier; needle-biopsy cohort
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 14
Issue: 1
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2016-01-01
Start Page: 19
End Page: 30
Language: English
ACCESSION: WOS:000367629000005
PROVIDER: wos
PUBMED: 26733552
DOI: 10.6004/jnccn.2016.0004
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James Eastham
    537 Eastham
Related MSK Work